Jubilant Life Sciences Limited, among other companies, has entered into a “non-exclusive licensing agreement” with Gilead Sciences – the maker of the remdesivir drug – to manufacture and sell Remdesivir in India, along with 126 other countries.

Earlier this month, remdesivir was given emergency use authorisation by the USFDA. Recent studies have shown that patients receiving remdesivir had a numerically faster time to clinical improvement. The drug remains investigational but is being seen as a potential treatment for COVID -19.

As per the latest update on the Gilead Sciences website, five generic pharmaceutical manufacturers based in India and Pakistan will further expand the supply of remdesivir. The agreements allow the companies – Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan – to manufacture remdesivir for distribution in 127 countries.

The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.